Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated

This article reports on a cost-effectiveness analysis of the original herpes zoster vaccine (ZVL) for the 65 year + population in France. The authors compared vaccinating all adults over 65 years versus adults from 70-79 years, over their lifetimes, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol 5D) utilities from the literature. Results showed incremental cost-effective ratios d between €9513 and €12,304 per quality-adjusted life…

This article reports on an analysis of the impact of universal childhood varicella vaccination on the incidence of herpes zoster (HZ) using dynamic transmission modelling and cost-effectiveness analyses. Scenarios that are considered differ by whether or not immune boosting is included, and whether or not reactivation of vaccine virus is possible. The authors report that health effects of varicella vaccination in scenarios with immune boosting are unevenly distributed: cohorts born just before introduction of vaccination and…

This 2008 Canadian study assessed the cost effectiveness of the Zoster Vaccine Live (ZVL) vaccine against herpes zoster (HZ) and post-herpetic neuralgia (PHN). The authors used a cohort model to estimate the burden of HZ and the cost-effectiveness of HZ vaccination from a ministry of health perspective using Canadian population-based data. They examined different ages at vaccination and conducted probabilistic sensitivity analysis.There are about 130,000 new cases of HZ, 17,000 cases of PHN and 20 deaths…